Lung disease company Spiration gets $22 million investment
This article was originally published in Clinica
Executive Summary
Spiration, which is developing devices for the treatment of lung disease, has raised $22m in a financing round, bringing its total raised to $36m. The private company will use the funds to bring its VALR surgical system to market and take its second product, an intra-bronchial tube, through the regulatory process.